Journal of Otology & RhinologyISSN: 2324-8785

Reach Us +1 850 754 6199
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

A Pilot Study of Quantitative Measurements of Nasal Function in Rhinitis and the Therapeutic Effects of Botulinum Toxin

A Pilot Study of Quantitative Measurements of Nasal Function in Rhinitis and the Therapeutic Effects of Botulinum Toxin

Objective: Symptoms of rhinitis can be attributed to the stimulation of cholinergic nerve endings, which leads to mucosal hypersecretion and an increase in nasal blood flow. As botulinum toxin is a powerful cholinergic blocker, the application of this toxin intranasally may help to decrease the symptom complex associated with rhinitis. A pilot study was designed to evaluate the use of hot wire airflow, measurement of stimulated secretions, and the effect of botulinum toxin on both. A quantitative assessment of this use in humans has never been performed.

Study Design: Double-blind, placebo controlled randomized control trial.

Methods: Botulinum toxin was injected into the inferior turbinates of 8 human subjects. Patients were their own controls, with each side randomized to receive onabotulinumtoxinA (BTX-A) (four 2.5 unit aliquots) or equivalent volume of normal saline.. Airflow was measured at baseline and each visit using hot-wire airflow device. Baseline and stimulated nasal secretions were collected on filter paper then weighed. The patients were followed monthly for a total of 4 months.

Results: There was a statistically significantly greater airflow on the BTX-A treated sides compared with control sides at 4 months. There was also a statistically significant decrease in stimulated secretions at 3 months. There was a notable trend toward reduction of resting secretions and stimulated secretions in the BTX-A treated sides during the treatment period. There was also a trend toward greater airflow in the BTX-A treated sides during the treatment period.

Special Features

Full Text

View

Track Your Manuscript

Share This Page

Media Partners

Associations